TTOO stock exploded 44% higher on September 11, 2019, on an analyst upgrade.

Canaccord analyst Mark Massaro maintained a Buy rating on T2 Biosystems, and raised his price target on the shares to $3.50 from $2.50, following a “positive business update call” that helped push T2 shares 60% higher and left the analyst “feeling better” about the company’s prospects.

TTOO stock explodes higher on analyst upgrade on September 11, 2019.

On September 10, 2019, T2 Biosystems announced that Premier, a healthcare improvement company, as part of their technology breakthroughs program, has awarded the company a breakthrough technology contract. The agreement will allow Premier’s members, including a network of more than 4,000 U.S. hospitals and health systems, to receive special pricing and access to T2 Biosystems’ T2Bacteria Panel and T2Candida Panel – technology that can rapidly detect sepsis-causing pathogens in three to five hours instead of days – to foster fast, accurate therapy of bloodstream infections. The contract is effective as of September 1, 2019.

Disclosure: We do not hold any position in TTOO stock.

T2 Biosystems In the News